Proteon Pharmaceuticals, a biotechnology company backed by seafood-focused investment fund Aqua-Spark, received a new cash injection of €21 million ($24.6 million) to accelerate commercialization of its products.
Poland-based Proteon uses naturally occurring microorganisms called bacteriophages -- essentially good viruses attacking and overtaking bad bacteria -- to reduce the need for antibiotics in farming.
The latest financing round was led by Nutreco, Aqua-Spark and PFR Life Science, a portfolio company of the Polish Development Fund (PFR).
